Aura Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

AURA$7.65-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Additional · Accumulated · Total
Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’
Shares · Amount · Capital · Deficit · Income (Loss) Amount · Equity
Balance, December 31, 2023	49,350,788		$—		$512,617		$(287,308)		$539		$225,848
Stock-based compensation expense	—		—		2,909		—		—		2,909
Employee Stock Purchase Plan issuance	12,314		—		95		—		—		95
Stock option exercises	51,180		—		158		—		—		158
Vesting of restricted stock	90,123		—		—		—		—		—
Unrealized loss on marketable securities	—		—		—		—		(521)		(521)
Net loss	—		—		—		(19,706)		—		(19,706)
Balance, March 31, 2024	49,504,405		—		515,779		(307,014)		18		208,783
Stock-based compensation expense	—		—		3,126		—		—		3,126
Employee Stock Purchase Plan issuance		—		—		—		—		—
Stock option exercises	24,245		—		83		—		—		83
Vesting of restricted stock	54,708		—		—		—		—		—
Unrealized loss on marketable securities	—		—		—		—		(201)		(201)
Net loss	—		—		—		(20,337)		—		(20,337)
Balance, June 30, 2024	49,583,358		—		518,988		(327,351)		(183)		191,454
Stock-based compensation expense	—		—		2,750		—		—		2,750
Employee Stock Purchase Plan issuance	12,163		—		82		—		—		82
Stock option exercises	127,433		—		634		—		—		634
Vesting of restricted stock	55,907		—		—		—		—		—
Unrealized gain on marketable securities	—		—		—		—		790		790
Net loss	—		—		—		(21,042)		—		(21,042)
Balance, September 30, 2024	49,778,861	$	-		$522,454		$(348,393)		$607		$174,668
Additional · Accumulated · Total
Common Stock · Paid-In · Accumulated · Other Comprehensive · Stockholders’
Shares · Amount · Capital · Deficit · Income (Loss) Amount · Equity
Balance, December 31, 2022	37,771,918		$—		$406,555		$(210,900)		$(72)		$195,583
Stock-based compensation expense	—		—		1,913		—		—		1,913
Employee Stock Purchase Plan issuance	6,635		—		56		—		—		56
Stock option exercises	21,549		—		145		—		—		145
Unrealized gain on marketable securities	—		—		—		—		27		27
Net loss	—		—		—		(17,466)		—		(17,466)
Balance, March 31, 2023	37,800,102		—		408,669		(228,366)		(45)		180,258
Stock-based compensation expense	—		—		1,931		—		—		1,931
Issuance of common stock under ATM facility	169,200		—		2,065		—		—		2,065
Stock option exercises	117,304		—		660		—		—		660
Unrealized loss on marketable securities	—		—		—		—		(178)		(178)
Net loss	—		—		—		(18,299)		—		(18,299)
Balance, June 30, 2023	38,086,606		—		413,325		(246,665)		(223)		166,437
Stock-based compensation expense	—		—		2,325		—		—		2,325
Employee Stock Purchase Plan issuance	8,276		—		72		—		—		72
Issuance of common stock under ATM facility	92,607		—		1,105		—		—		1,105
Stock option exercises	29,228		—		202		—		—		202
Unrealized gain on marketable securities	—		—		—		—		89		89
Net loss	—		—		—		(18,512)		—		(18,512)
Balance, September 30, 2023	38,216,717		$—		$417,029		$(265,177)		$(134)		$151,718

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.